The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer

Authors: Yoshida, T.; Tanaka, S.; Mogi, A.; Shitara, Y.; Kuwano, H.

Source: Annals of Oncology, Volume 15, Number 2, February 2004 , pp. 252-256(5)

Publisher: Oxford University Press

Buy & download fulltext article:

OR

Price: $44.11 plus tax (Refund Policy)

Abstract:

Background:

Cyclin B1 has an important role in the G<inf>2</inf>–M phase transition of the cell cycle. Wee1 delays mitosis by suppressing the activity of the Cyclin B1/cdc2 complex. The objective of the present study was to elucidate the clinicopathological and prognostic significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer (NSCLC).

Patients and methods:

An immunohistochemical assessment of Cyclin B1 and Wee1 expression was performed in 79 patients with NSCLC.

Results:

The expression of Cyclin B1 was correlated with differentiation (P = 0.0423) and vascular invasion (P = 0.001). Patients with overexpression of Cyclin B1 had higher mean values for both the Ki-67 proliferative index (Ki-Index) (P <0.0001) and proliferating cell nuclear antigen labeling index (PCNA-LI) (P <0.0001), and a poorer prognosis (P = 0.0068). Patients lacking expression of Wee1 had a higher recurrence rate (P = 0.0084) and a poorer prognosis (P = 0.0457), and tended to have higher Ki-Index and PCNA-LI values. Multivariate analysis suggested that both Cyclin B1 (P = 0.0244) and Wee1 (P = 0.0444) expression were significant prognostic factors.

Conclusions:

These findings suggest that Cyclin B1 expression could be a significant prognostic parameter in NSCLC. The loss of Wee1 expression may have a potential role in promoting tumor progression and may be a significant prognostic indicator in NSCLC.

Keywords: cell cycle; Cyclin B1; differential PCR; immunohistochemistry; non-small-cell lung cancer; Wee1

Document Type: Research article

DOI: http://dx.doi.org/10.1093/annonc/mdh073

Publication date: 2004-02-01

More about this publication?
  • Annals of Oncology is a multidisciplinary journal that publishes articles addressing medical oncology, surgery, radiotherapy, paediatric oncology, basic research and the comprehensive management of patients with malignant diseases.
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page